Back to results
US 2024/0199603 A1Published application
Hpk1 antagonists and uses thereof
AssigneeNimbus Saturn, Inc.
InventorsNeelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Benjamin WHITTAKER, William SINKO, Shawn WATTS, Mark Anthony ASHWELL, Byron Scott DELABARRE
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
Claims26
1-20. (canceled)
A method of inhibiting HPK1 in biological sample comprising contacting the sample with a compound of formula I:
- or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, wherein:
- Z is CR or N;
- X is a —O—, —NR—, —S(O)—, —S(O)—, —S(O)NR—, —C(O)—, —C(O)O—, —C(O)N(R)O—, —OC(O)—, —OC(O)NR—, or —N(R)C(O)O—;
- R1 is selected from phenyl;
- a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
- a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- and an 8-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- each of which is substituted with q instances of RC;
- R2 is selected from C1-6 aliphatic;
- phenyl;
- a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
- a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- each of which is substituted with q instances of RC;
- or R2 is selected from —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —N(R)NR2, —N(R)S(O)2NR2, —N(R)S(O)2R, —N═S(O)R2, —S(NR)(O)R, and —N(R)S(O)R;
- each instance of R3 is independently hydrogen or an optionally substituted C1-6 aliphatic group;
- each instance of RC is independently oxo, halogen, —CN, —NO2, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —N(R)NR2, —N(R)S(O)2NR2, —N(R)S(O)2R, —N═S(O)R2, —S(NR)(O)R, —N(R)S(O)R—, —N(R)CN, —P(O)(R)NR2, —P(O)(R)OR, or —P(O)R2;
- or each instance of RC is independently an optionally substituted group selected from C1-6 aliphatic;
- phenyl;
- naphthyl;
- a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
- a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, phosphorous, silicon and sulfur;
- a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 5-8 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- and a 6-11 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- each of which is substituted with r instances of R and s instances of RD;
- each instance of RD is independently oxo, halogen, —CN, —NO2, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —N(R)NR2, —N(R)S(O)2NR2, —N(R)S(O)2R, —N═S(O)R2, —S(NR)(O)R, —N(R)S(O)R— —N(R)CN, —P(O)(R)NR2, —P(O)(R)OR, or —P(O)R2;
- each R is independently hydrogen, —CN, halogen, or an optionally substituted group selected from C1-6 aliphatic;
- phenyl;
- naphthyl;
- a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
- a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 5-8 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 6-10 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- and a 6-11 membered saturated or partially unsaturated bicyclic carbocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- or;
- two R groups on the same nitrogen are taken together with the nitrogen to form an optionally substituted 4-7 membered monocyclic saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- m is 0, 1, or 2;
- each q is independently 0, 1, 2, 3, or 4;
- each r is independently 0, 1, 2, 3, or 4;
- and
- each s is independently 0, 1, 2, 3, or 4.
47 more elements
A method of treating an HPK1-mediated disorder, disease, or condition in a patient comprising administering to said patient a compound of formula I:
- or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, wherein:
- Z is CR or N;
- X is a —O—, —NR—, —S(O)2—, —S(O)—, —S(O)NR—, —C(O)—, —C(O)O—, —C(O)N(R)O—, —OC(O)—, —OC(O)NR—, or —N(R)C(O)O—;
- R1 is selected from phenyl;
- a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
- a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- and an 8-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- each of which is substituted with q instances of RC;
- R2 is selected from C1-6 aliphatic;
- phenyl;
- a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
- a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- each of which is substituted with q instances of RC;
- or R2 is selected from —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R— —N(R)C(O)NR2, —N(R)C(NR)NR2, —N(R)NR2, —N(R)S(O)2NR2, —N(R)S(O)2R, —N═S(O)R2, —S(NR)(O)R and —N(R)S(O)R;
- each instance of R3 is independently hydrogen or an optionally substituted C1-6 aliphatic group;
- each instance of RC is independently oxo, halogen, —CN, —NO2, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —N(R)NR2, —N(R)S(O)2NR2, —N(R)S(O)2R, —N═S(O)R2, —S(NR)(O)R, —N(R)S(O)R, —N(R)CN, —P(O)(R)NR2, —P(O)(R)OR, or —P(O)R2;
- or each instance of RC is independently an optionally substituted group selected from C1-6 aliphatic;
- phenyl;
- naphthyl;
- a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
- a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, phosphorous, silicon and sulfur;
- a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 5-8 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 6-11 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- and a 6-11 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- each of which is substituted with r instances of R and s instances of RD;
- each instance of RD is independently oxo, halogen, —CN, —NO2, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —N(R)NR2, —N(R)S(O)2NR2, —N(R)S(O)2R, —N═S(O)R2, —S(NR)(O)R, —N(R)S(O)R, —N(R)CN, —P(O)(R)NR2, —P(O)(R)OR— or —P(O)R2;
- each R is independently hydrogen, —CN, halogen, or an optionally substituted group selected from C1-6 aliphatic;
- phenyl;
- naphthyl;
- a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
- a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 5-8 membered saturated or partially unsaturated bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 6-10 membered saturated or partially unsaturated spirocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- and a 6-11 membered saturated or partially unsaturated bicyclic carbocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- or;
- two R groups on the same nitrogen are taken together with the nitrogen to form an optionally substituted 4-7 membered monocyclic saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- m is 0, 1, or 2;
- each q is independently 0, 1, 2, 3, or 4;
- each r is independently 0, 1, 2, 3, or 4;
- and
- each s is independently 0, 1, 2, 3, or 4.
47 more elements
26-27. (canceled)
Dependencies are inferred from the claim text.